Name: 2nd Annual MarketsandMarkets ImmunoBio Series
Start: 2024-10-14
End: 2024-10-15
Location: Freiburg, Germany

WHAT TO EXPECT

Preclinical and Translational Immuno-Oncology Developments
Biomarker Discovery Techniques: Explore novel strategies, including genomics, proteomics, metabolomics, and bioinformatics, to identify cutting-edge biomarkers in oncology.
Precision Medicine Tailoring: Understand the pivotal role of biomarkers in customizing immunotherapy for individual patients, enhancing efficacy, and minimizing side effects.
Personalizing Cancer Treatment- Challenges and Opportunities
Rigorous Biomarker Validation: Learn strategies and overcome challenges in validating biomarkers for clinical use, ensuring robust and reliable results.
Bioinformatics and AI Analysis: Attend sessions on biomarker data analysis, employing machine learning and artificial intelligence approaches for comprehensive insights.
Biomarker-Based Cancer Diagnostics Development: Gain insights into the development and commercialization of diagnostic tests and platforms based on biomarkers.
Next Gen Antibodies and Targeted Therapies
Immune Checkpoint Inhibitors and Combination Therapies
Tumor Microenvironment and Cancer Biomarkers
CAR-T cell therapy, T Cell Therapy, Adoptive Cell Therapy
Cancer Vaccines and Cancer Microbiome
Collaboration for Advancement: Explore sessions on fostering collaboration among academia, industry, and government agencies to drive biomarker research forward.

Cutting-Edge Insights: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer and immunology.
Innovative Immunotherapy: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
Networking and Collaboration: Connect with industry leaders, researchers, and peers. Foster collaborations, engage in thought-provoking discussions, and explore partnership opportunities.
Professional Development: Enhance your skills with workshops on cancer biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for biomarker and IO research.
Practical Applications: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
Personal and Industry Growth: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research and immunotherapy.

Engage in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
PRE-CLINICAL AND TRANSLATIONAL IO & IMMUNE CHECKPOINT BLOCKADES
Keynote Presentation - Unveiling Tumor Microenvironment Resistance Targets with the iOTarg Screening Platform - Featuring IOMX-0675, a LILRB1 and LILRB2 Cross-Specific Dual-Targeting Antibody Adriana Turqueti Neves, Associate Director, iOmx Therapeutics AG	09:00 - 09:30
Reserved Slot for Platinum Sponsor	09:30 - 10:00
Reserved Slot for Gold Sponsor	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
HLA-I and HLA-II Immunopeptidome Profiling and its use in Studies from Discovery to Clinic Anamarija Pfeiffer, Senior Scientific Project Manager, Biognosys	11:15 - 11:45
Targeting Dendritic Cells to make Cancer Cell Death Immunogenic Raj Mehta, Chief Executive Officer, Adendra Therapeutics Ltd	11:45 - 12:15
Arenavirus-based immuno-virotherapy: efficacious anti-tumor activity combined with advantageous effects on the tumor microenvironment (TME) Sarah-Kim Friedrich-Becker, Senior Principal Scientist, Abalos Therapeutics GmbH	12:15 - 12:45
Challenges and opportunities for digital biomarkers from histopathology (IHCs) Philipp Wortmann, Director, Translational Science, Astrazeneca	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
ROLE OF CANCER BIOMARKERS IN PERSONALIZED MEDICINE
Immune checkpoint inhibitors: insights and advances from CRO perspective Holger Weber, Head of In Vivo Pharmacology, Reaction Biology Europe GmbH	14:15 - 14:45
Assessing the Safety and Efficacy of ctDNA in Augmenting Immunotherapy Interventions	14:45 - 15:15
Unlocking the Potential of Multi-omics: Bridging Biomarkers and Personalized Therapies	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDCline) Eric Halioua,* President & Chief Executive Officer, PDC*line pharma SA	16:30 - 17:00
Panel Discussion: Opportunities and Challenges in Biomarker Testing: Comparing Oncology and Non-Oncology Perspectives	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:30

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
INNOVATIVE STRATEGIES IN IMMUNOTHERAPY AND BIOMARKERS DEVELOPMENT
Keynote Presentation - Reserved for Platinum Sponsor	09:00 - 09:30
Neuropilin-1 (NRP1) as novel target for antisense oligonucleotides (ASOs) to treat patients with solid tumors Frank Jaschinski, CSO, Secarna Pharmaceuticals	09:30 - 10:00
Leveraging a Novel Non-Gene Edited Platform to Improve Efficacy and Safety of CAR T-Cell Therapies Marine Blackman, Research Scientist, Celyad Oncology	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Solution Provider Presentation-Reserved for Silver Sponsor	11:15 - 11:45
Validation of melanoma non-responders fingerprint fit, to the mechanism of action JJP-1008. Tomasz Grabowski, Head of Preclinical Development, JJP Biologics	11:45 - 12:15
Delving into the Mechanism of Action of Neoantigen Antibodies to Aid the Development of Highly Effective Combination Strategy Towards More Successful Therapies Philip Arlen, Chief Scientific Officer, Senior Vice President, Diverse Biotech	12:15 - 12:45
Predicting Patient Response to Checkpoint Inhibitors Jens Kringelum, VP, AI & Innovation, Evaxion Biotech	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
LATEST DEVELOPMENTS & TRENDS IN IO & BIOMARKER RESEARCH
Early diagnosis of infectious diseases using DNA/RNA-based molecular methods Jinyu Shan, Professor, University of Leicester	14:15 - 14:45
Innovative Safety Biomarker Applications to Drug Development	14:45 - 15:15
Regulatory Framework for Biomarker Diagnostics: Insights and Strategies	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care	16:30 - 17:00
Closing Remarks from the Chairperson	17:00 - 17:00